The CMS rule on average drug manufacturer price is due to be finalized in August. It could lead to lower Medicaid pharmacy reimbursements in states that now overpay for generic drugs, Adam Fein writes. The proposed AMP rule is related to an Affordable Care Act provision instructing CMS to develop a new formula for determining the maximum pharmacy dispensing fees that a state Medicaid agency can reimburse.

Full Story:
Drug Channels

Related Summaries